Bob Groesbeck on the Vegas Retail Rollercoaster of 2020 | #HashtagFinance

CSE’s Barrington Miller chats with Bob Groesbeck, Co-CEO of Planet 13 Holdings Inc. (CSE:PLTH) about his company’s challenges – and newfound opportunities – serving customers through their Vegas SuperStore during the pandemic:

0:35 – Introducing Planet 13 holdings – an entertainment company
1:35 – Life since MJBiz in Vegas
4:33 – Having the team to make the transition to delivery possible
7:03 – The Planet 13 product offerings – expansion of the house brand
10:24 – Current tourism trends
12:58 – What the company plans to do with its recently raised funds
14:49 – Post-COVID plans
16:44 – Origin of the Planet 13 name

Planet 13 is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Related links
www.planet13holdings.com
https://thecse.com/en/listings/life-sciences/planet-13-holdings-inc

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

Field Trip Health Ltd. Joins the CSE at Our First Virtual Market Open

The CSE proudly welcomed Field Trip Health Ltd. (CSE:FTRP) to join the Exchange in our first virtual Market Open, on October 6th, 2020. 

Field Trip Health is a global leader in the development and delivery of psychedelic therapies for mental health, including depression. The company conducts advanced research on plant-based psychedelics and is leading the development of the next generation of psychedelic molecules. Currently operating within North America and via Field Trip Digital, the company’s technology division, Field Trip Health blends psychedelic-enhanced therapy, mindfulness, and self-care with a series of sessions with trained psychotherapists. This enables them to offer a more personalized approach to mental wellness, as opposed to traditional pharmaceutical and psychiatric treatments. 

In celebration of the momentous occasion, CSE CEO Richard Carleton stated, “It’s a real pleasure in fact, it’s our favourite part of all of our jobs: to welcome new issuers to the Exchange.” He remarked, “[The CSE is] very active in the psychedelic space. We’ve got many, many people who are very excited [about] the therapeutic benefits, the lifestyle benefits, and wellness and improvement in overall human health that this sector promises.” 

James Black, the CSE’s Vice President of Listings Development, added, “Welcome to the Exchange. Thanks for being a part of the family. We’re very, very excited to welcome you today and, for the first time, to give you a virtual welcome. We look forward to working with you. We’re really proud of the listing; we’re proud of everything that you’re aiming to do. Let’s be a part of something successful.”

Several members of the Field Trip Health team were present at the virtual event, including Founder and Executive Chairman Ronan Levy, who led the countdown and “rang” a makeshift “opening bell” of his own. 

For more details about the CSE, including information on upcoming Market Opens, please visit the CSE website or follow us on social media.

The CSE Announces Thomas S. Caldwell’s Departure and Four New Directors Elected to the Board

Last month, Thomas S. Caldwell retired from the Board of Directors of the Canadian Securities Exchange and stepped down as Chairman, a role he had filled since 2012. The move was prompted by a new recognition order from the Ontario Securities Commission requiring the Exchange to have an independent director serve as Chairman. 

Mr. Caldwell, President and CEO of Urbana Corporation, played an enormous role in the CSE’s success. In 2012, Urbana led the recapitalization of CNSX Markets Inc., which operates the CSE. Mr. Caldwell was intimately involved in supporting the CSE’s strategy and spearheading its growth. At the time of Urbana’s investment, the CSE had 189 listings, average daily trading volume of 4.22 million shares, and a cumulative market capitalization for all its securities of $1.18 billion. Today, the CSE is a substantial global stock exchange with 610 listings, average daily trading volume of 101.62 million shares, and a cumulative market capitalization of $25.33 billion.

“It is impossible to overstate Tom Caldwell’s contribution to the success of the Canadian Securities Exchange,” said Richard Carleton, CSE Chief Executive Officer. “The success we have achieved in capitalizing on growth opportunities, including those in the cannabis sector, is directly attributable to his leadership. To put it simply, the CSE would not be where it is today without him.”

“I couldn’t be prouder of what the CSE team has achieved over the last eight years,” said Mr. Caldwell. “Back in 2012, I recognized that Canada needed a strong alternative platform that truly met the needs of emerging issuers. Today, there is no doubt that the CSE has fulfilled its promise and is recognized as a preferred public market option for leading entrepreneurs.”

Steve Blake has assumed the role of Chairman of the CSE. Mr. Blake has been a director of the CSE since 2018, and he has more than 20 years of experience in senior financial roles at a range of companies. He was most recently Chief Operating Officer of the Child Development Institute, an accredited children’s mental health agency in Toronto. He previously served as Chief Financial Officer for The Canadian Depository for Securities Limited.

“I am honoured to be named Chairman of the Canadian Securities Exchange,” said Mr. Blake. “While no one can truly replace Tom Caldwell, I am confident that we have an outstanding leadership team in place that is well equipped to drive the next stage of the CSE’s growth and continue to deliver superior service to all of its stakeholders.” 

Four New Directors Elected

At the CSE’s Annual and Special Meeting of Shareholders last month, four new, highly talented nominees were elected to the Board of Directors: Hema Barkhouse, Michael Bluestein, Brendan T.N. Caldwell, and Eric Sites. Both Ms. Barkhouse and Mr. Bluestein are independent directors. Three of the CSE’s long-time directors did not stand for re-election: Thomas S. Caldwell, George Elliott, and Joel Strickland.

“We are delighted to welcome four new directors to the Board of the Canadian Securities Exchange,” said Richard Carleton, “They are replacing three truly outstanding directors. Tom, George, and Joel made enormous contributions to the CSE and oversaw a period of significant growth for the Exchange.”

Hema Barkhouse is Vice President, Accounting and Controls at Canadian Tire Corporation Ltd. She has more than 25 years of experience in the retail, consumer packaged goods, telecom, and financial services industries. In addition to Canadian Tire, Ms. Barkhouse has held executive roles at Loblaw Companies Ltd., George Weston Ltd., and Bell Canada.

Michael Bluestein is a Corporate and Securities Lawyer and the Founder of the CC Corporate Counsel P.C. law firm. He has more than 13 years of experience in M&A, corporate finance, registration, compliance, and securities law. He has advised numerous reporting issuers and helped multiple start-ups achieve their goals, from incorporation to successful exits.

Brendan T.N. Caldwell is President, CEO, and CIO of Caldwell Investment Management. He is also Co-Portfolio Manager of Caldwell’s major exchange-related investments, including Urbana Corporation and the Caldwell Growth Opportunities Trust. His securities exchange memberships have included Toronto, New York, the Chicago Board Options Exchange, the Kansas City Board of Trade, and the American Stock Exchange.

Eric Sites is Vice President and Portfolio Manager at Horizon Kinetics LLC, a firm he joined in 2004. He is a member of the firm’s research team and a member of its investment team for certain Horizon private investment vehicles and other registered investment companies. Mr. Sites currently serves on the Council of the Bermuda Stock Exchange, where he heads the New Business Development Committee.

In addition to the four new members, the Board consists of Steve Blake (Chair), Jim Dale, and Jeffrey MacIntosh.

“With our strong new directors and outstanding management team, the Canadian Securities Exchange is well positioned to continue fulfilling its mandate to be the exchange of choice for entrepreneurs,” said Mr. Blake.

Setti Coscarella on the Better Way to Smoke | #HashtagFinance

CSE’s Phillip Shum chats with TAAT Lifestyle & Wellness Ltd. (CSE:TAAT) CEO Setti Coscarella about their objective to introduce an innovative, experience-driven alternative to tobacco cigarettes for tobacco smokers who aspire to leave nicotine behind.

Here’s an overview of what they cover in this episode of #HashtagFinance:

0:35 – Introducing Setti and the TAAT mission
1:57 – Setti’s background with Phillip Morris’ heat – not burn – product (IQOS)
4:15 – How Hemp/CBD cigarettes emulate a tobacco/nicotine smoke
7:43 – Manufacturing and marketing differences between hemp and tobacco cigarettes
11:53 – Recently secured manufacturing partner and patent filing
14:42 – Where TAAT is currently being sold and tested
16:37 – What you didn’t know about the tobacco industry
18:35 – Setti’s goals as the new CEO of TAAT
19:45 – TAAT’s opportunity in the 900Bn global tobacco market

Related links
https://thecse.com/en/listings/life-sciences/taat-lifestyle-wellness-ltd
https://taatusa.com/ 

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

NexTech AR Solutions: Evan Gappelberg’s latest venture is a big bet on the future of augmented reality

Imagine you are shopping online for a new couch. You find one you like, but it is hard to know if the colour quite matches the rest of your furniture, and the retailer’s website only has a 2D photo of it from the front.

Now imagine being able to view and rotate the couch in full 3D and use your phone to project a volumetric image that you can place, pinch, zoom and walk around, right into your living room.

That’s one example of how augmented reality is changing the way people shop, and shopping is just one of four verticals NexTech AR Solutions (CSE:NTAR) is pursuing in the sector.

Chief Executive Officer Evan Gappelberg calls it “ARitizing,” and his company has done it to everything from furniture to firearms to human holograms.

A self-described crazy entrepreneur looking for the next trillion-dollar megatrend, idea or industry, Gappelberg prides himself on identifying the next big thing. He has invested in dozens of successful ventures and led companies in the software and cannabis spaces, and three years ago he found his latest muse, augmented reality.

Augmented reality is a new concept to most people. Tell us how NexTech AR was formed and why you became interested in the industry.

I spent 30 years on Wall Street, and on Wall Street you always have to identify the hot stock in the hot sector. In the 1990s, it was the internet. Then energy and real estate took centre stage in the early 2000s. And then in 2008 the iPhone kicked off a paradigm shift, with mobile phones creating an entire new industry and stock sector called social media. Then, in 2015, everything switched to cannabis investing. Now and in the 2020s, technology, and specifically AR, AI and IoT, will create new billion-dollar companies seemingly overnight.

To be a successful investor I have followed the flow of money, which has made me kind of a generalist. If oil and gas is a hot sector, I do a ton of industry research and I become an expert in everything to do with oil and gas. Same for technology, healthcare, social media, etc. I research industries as I get deeper into them, and I start to understand how they work, which makes investing life interesting since I’m always learning something new.

I identified cannabis as the next big wave in 2011. It took a few years, but I brought in seed capital for a cannabis company that went public in Canada in 2016, and in 18 months it went up by 40 times. It was about identifying the trend and getting in before the big wave, then riding the wave, although to avoid a round trip you need to be able to see if the sector you are in is about to go through growing pains or get disrupted. Most of my investments are not buy and hold, although I did take a gaming company called Take-Two Interactive Software public in the 1990s, and today it has a $15 billion market cap. That was one I should have held.

Not to say I haven’t had my fair share of mistakes, but I do have a solid track record of picking industries that really have the potential to be grand-slam-home-run investments.

That brings us to augmented reality. I was introduced to AR in late 2017, and as soon as I saw it I knew that it was going to be the next big thing.

To take advantage of the coming AR megatrend, I founded NexTech AR Solutions in January 2018. Our first product was ARitize, which is an app that went live in 2018. It’s a white label AR app that we are having a lot of success with. It can create AR experiences and allow us to demo augmented reality to our enterprise clients. So that is how we got started.

As CEO and Founder of NexTech, I put my money where my mouth is by investing in my own company. I have invested millions in NexTech, and currently I take 100% of my salary in stock, plus I have made four purchases of the company’s shares this year alone. The only reason to do that is because I think the company is going to be worth a lot more over the following 12 to 24 months.

How does your technology augment a user’s reality?

We were first to market with a webAR e-commerce solution, which we launched in early 2019. It allows customers, on any web browser without requiring an app, to just click on a web icon and view a 3D model in augmented reality. And if they are on a mobile device, the product shows up as an AR digital twin.

We recently signed up an eyewear company, Clearly.ca, and are ARitizing seven different styles of glasses for them. We’ve created a special 3D/AR advertising platform where you can put your face up to your phone or up to your computer screen, and the glasses will appear on your face, so you can try them on virtually before you buy.

It sounds as if the possibilities are endless. What does the business model for such an evolving technology look like?

It’s a SaaS business model. You can download the ARitize360 app for free, and then after that you pay for usage. It can cost as little as $40 to $99 for an AR scan, and the goal is to get it down to $10 to $20 per scan. If we can do that, we expect to see mass adoption.

The cost has to do with human touch-up, as the less interaction there is with the asset, the cheaper it is. We are currently the only company that has virtually zero human interaction, so nobody needs to touch it.

Businesses can then use those assets on our 3D/AR ad network, which launched this year.

Most medium-sized businesses are spending $50,000 a month on ads, and we have proven that 3D ads generate a 300% increase in conversions. We have done testing on an e-commerce site we own, vacuumcleanermarket.com, and the 3D ads we ran brought a 300% jump in sales.

And if you can grow something 300% by switching to our ad network, you are going to do it. We get a percentage of those dollars, so it’s less about how much money we make on the 3D asset itself and more about how companies use that asset to drive sales for their business.

The COVID-19 pandemic is affecting companies in different ways. What has it meant for NexTech so far?

Well, we had a platform called ARitize University, which has morphed into our recently acquired InfernoAR virtual events and video conferencing platform, which is surging right now.

InfernoAR is the only platform that offers virtual video conferences with augmented reality. So, if you’re watching a presentation and there’s a product on the screen, by using our ARitize app you can take your phone and scan a QR code, which literally pulls out of the screen whatever product it is you’re viewing and places it in the room with you. We see this as transformative new technology.

InfernoAR is booming. Because so much has been shut down by COVID-19, governments, businesses, universities, healthcare providers, really everyone is looking for a way to communicate remotely, and we have the only immersive platform driven by our AR that allows you to create human holograms or to have 3D/AR product views, all built into this video conferencing platform.

It’s funny watching people try it for the first time, because they will literally press their nose against the screen of their computer to get a closer look. I literally see them move all the way in, because they cannot believe what they are seeing.

We recently doubled our sales force, as we continue to sign up new customers, and we expect to double it again this year. Because we are in the fastest growing market sector, which is the technology sector enabling the work-from-home and shop-from-home paradigm shift, our business really has the potential to explode and grow exponentially, similar to the way that Zoom has grown recently. Zoom just reported that revenue grew 169% for their last quarter, while we reported 169% growth for last month alone, so similarities do exist.

You clearly have unique products that fit the times. How are sales going?

We had record revenue and record gross profit in the month of May. We saw $1.3 million in revenue and $800,000 in gross profit, which is a 169% increase year over year on the revenue side and a 290% increase on the profit side.

We are firing on all cylinders right now. Virtual events, augmented reality, e-commerce – they’ve never been stronger. And we see that trend continuing. June should be better than May, and July better than June. We are projecting $15 million to $20 million in revenue in 2020, and possibly double that in 2021, up from $6 million in 2019.

It goes without saying that a company such as NexTech is constantly evolving. What’s on your radar for the next little while?

There are a few things on the horizon. First is to continue to succeed with our virtual video conference platform and build up our sales force.

We also have our 3D/AR ad network that is starting to gain traction and show sales wins, so we are going to have to build a team around that and allow it to scale.

Lastly, we are looking at acquisitions. We have made four acquisitions since we went public, and we continue to look for more.

There are some exciting opportunities out there in the world of augmented reality. There are a lot of little start-ups that would fit right in with NexTech and help us to push our technology forward without having to spend time and money on development costs.

This story was featured in the Public Entrepreneur magazine.

Learn more about NexTech AR Solutions
at https://www.nextechar.com/.

Anthony Brown on Computing the New Digital Era | #HashtagFinance

CSE’s Anil Mall chats with Anthony Brown, CEO of AMPD Ventures Inc. (CSE:AMPD), about his company’s ambitions in providing high-performance cloud and computing solutions for low-latency applications, including video games and eSports, digital animation and visual effects, and big data collection, analysis and visualization.

Here’s an overview of what Anil and Anthony cover in this edition of the #HashtagFinance podcast:

0:35 – Catching-up with AMPD CEO Anthony Brown.
3:10 – What does it mean to be a “Next Generation Digital Infrastructure” company?
4:45 – High Performance Computing vs Commodity Computing.
6:00 – The potential of the global eSports, virtual reality, and digital effects sectors.
8:55 – Recent announcements re: AccelByte and Versatile Media.
13:06 – The financial impact on the film and television industry.
16:15 – Being the company that provides the picks and shovels for the gold rush of virtual production.
20:15 – The Supercluster Project w/ an airline manufacturing plant.
24:20 – How Anthony’s passion comes from his 30 years of experience in the industry.
27:15 – What Stephen Hynes brings to the AMPD team.
30:15 – The Waterfall Building and how it illustrates urban efficiency.
33:35 – Outlook for the remainder of the year.
35:35 – The coming Virtual Reality metaverse aka Ready Player One.

Related links
https://thecse.com/en/listings/technology/ampd-ventures-inc 
https://ampd.tech 

A legal disclaimer for AMPD Ventures Inc. can be found here: https://ampd.tech/legal/general-disclaimer/

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

InnoCan Pharma: Better delivery of CBD to the body holds the potential to lower costs and broaden treatment options

CBD is advertised as providing relief for anxiety, depression and post-traumatic stress disorder, among other benefits. Its popularity reflects, in part, that it is positioned as non-psychoactive while still providing access to many aspects of the cannabis plant that are good for human health.

The challenge is to create a more precise and efficient method for delivering CBD into a patient’s body, preferably allowing for synergistic effects and/or controlled release.

InnoCan Pharma (CSE:INNO), based in the Israeli tech hub of Herzliya, has found what might be the golden ticket for CBD-integrated pharmaceutical technology in the form of a method to inject CBD into the body.

InnoCan and Ramot, Tel Aviv University’s business engagement centre supporting scientific discovery, are collaborating on a revolutionary exosome-based technology that targets both central nervous system indications and COVID-19 coronavirus symptoms, as CBD-loaded exosomes have the potential to provide anti-inflammatory properties to help infected lung cells recover. Public Entrepreneur spoke with InnoCan Chief Executive Officer Iris Bincovich recently about this project and other exciting directions the company’s technologies are taking.

Tell us about your personal background and how InnoCan came to be.

My background is in healthcare, working in the international pharmaceutical and cosmetic and medical device arena, and I hold a Bachelor of Science degree in chemistry from the Israel Institute of Technology.

I have experience developing strategies and building brands in the dermatology space, and I have worked and communicated with top pharmaceutical companies and cosmetic companies, including Johnson & Johnson, Estée Lauder and L’Oréal.

InnoCan Pharma was established by Yoram Drucker, an Israeli serial intrapreneur with experience founding companies in the field of stem cells; Ron Mayron, former CEO of Teva Israel, Teva Pharmaceutical being one of the most important generic drug producers in the world; plus Nir Avram, who was on the pharmaceutical innovation team at Perrigo and holds a number of patents, not to mention more than 30 years of experience developing topicals. We bring worldwide experience in healthcare and nearly 20 years of international marketing, business development and sales experience. I have led and managed hundreds of successful international transactions in the OTC cosmetics and dermatology sector.

InnoCan gives me an opportunity to utilize my experience, take my knowledge in the healthcare markets and combine it all into a company that today is active in three different segments.

We are involved in several pharma projects with the Hebrew University of Jerusalem and with Tel Aviv University to better administer cannabinoids into the body with innovative delivery platforms and potential to treat several diseases.

We have also developed a line of over-the-counter topicals, Relief & Go, targeting a variety of skin conditions associated with issues like pain relief. Our pain relief spray provides a fast-action muscle relaxant and pain relief. It contains an analgesic blend of active ingredients, with isolated CBD to provide temporary relief of muscle and joint pain.

And we developed a line of CBD-integrated derma cosmetics, SHIR, whose formulations feature a tailored blend of active ingredients and technologies.

Let’s talk about the technology itself.  How is the company using exosomes and CBD?

We are developing a new platform that delivers cannabinoids in an improved way into the body. Our latest project is a collaboration targeting the COVID-19 virus with Tel Aviv University and Professor Daniel Offen, who heads the Neuroscience Laboratory at the Felsenstein Medical Research Center.

Exosomes have the ability to target damaged cells like a targeted missile, improve regeneration and assist in their recovery. Together with Professor Offen, an experienced researcher on cell and gene therapy in neurodegenerative diseases, we are looking to develop new technology that might be applicable to several indications.

Professor Offen is a co-founder of several biotechnology companies developing therapies for neurological disorders. One of them, BrainStorm Cell Therapeutics, developed cell treatment for ALS patients and is now in Phase III clinical trials.

Along with Professor Shulamit Levenberg of Technion, the Israel Institute of Technology, he previously utilized loaded exosomes administered by intra-nasal spray into rats with severe spinal cord injuries. The results were dramatic. Within a few weeks, the rats began to walk again.

With COVID-19, most people die from a secondary infection and lung or multi-organ failure. CBD is highly anti-inflammatory, and CBD-loaded exosomes, which we refer to as CLX, may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells.

The lungs are the organ most affected by COVID-19, so the CLX are expected to be administered by inhalation.

How far along in the development process are you?

We are in the preclinical stage, which we estimate will take nine to 12 months. We will begin production of exosomes loaded with CBD and then do in-vitro proof of concept in several models.  From there, we will do animal proof-of-concept models and then safety testing.

InnoCan’s strategy is to combine R&D with commercial experience. Professor Offen has more than 20 years of experience working with stem cells and exosomes, and he has already established companies developing therapies for neurological diseases.

How do these different delivery methods compare to taking CBD oil orally?

We are developing a unique technology with Professor Barenholz from the Hebrew University to enable the injection of CBD into the body. When you take cannabinoids orally, about 80% of it is destroyed by enzymes of the liver. Patients overload to achieve a therapeutic level.  More than that, the dose is not controlled systematically. In each case, a drop of oil is put below the tongue and it might take some time from administration until therapeutic effect is achieved. Size and therapeutic effect can differ from one drop to the next. We are proposing a much more controlled and effective delivery system.

CBD is an oil molecule that normally cannot be easily injected into the body. But once isolated inside a capsule, such as a liposome, it could be injected. Liposomes are small vesicles that could entrap a substance inside.

Imagine a child with epilepsy – which there is already an FDA-approved CBD drug for – having a seizure; today he needs to be under close care, to be given the medicine, it will take a few minutes until the effect begins, and so on. InnoCan’s approach could be different. We are looking at a solution where the child will have a smartwatch connected to a pump with injectable CBD-loaded liposome. Then, instead of the child having a seizure, maybe falling to the floor and needing someone to administer CBD, the watch will sense the seizure and instruct the pump to inject a specific amount of CBD into the body. Precise delivery of CBD immediately could assist in relieving the seizure.

And this is just one application. For an epilepsy seizure, the CBD would be released immediately, but the liposomes can also be multi-layered to prolong the release of the CBD. We are developing a platform for several potential indications.

For example, for people suffering from chronic pain, we may be able to offer an injection once a week, and over time one could have a consistent release of CBD into the body.

Professor Barenholz has already developed a liposome-based breast cancer drug, named Doxil, that was licensed by Johnson & Johnson. We are working with people who have done this before and are connected to the commercial side. This is the value-driven proposition of the company.

Do you have any other products headed for commercialization?

We have our over-the-counter topicals, patent pending products that combine CBD and other active ingredients targeting skin conditions, pain relief, as well as for itchiness.

We also have a line of premium cosmetic products for women. Those products are now being produced by two manufacturers: one in New Jersey for the US market, and one in Portugal for Asia and Europe. Sales will start in the second half of 2020.

Eventually, the world will open up again, and there are lots of plans for the future, including additional distribution contracts for the topicals.

In Canada, we are in dialogue with several companies to enable local distribution. We need to collaborate with a local licensed producer in order for them to manufacture, distribute and sell our topicals to the different provinces. And I can say that we are in the screening process of who is going to be our local partner there.

This story was featured in the Public Entrepreneur magazine.

Learn more about InnoCan Pharma
at https://innocanpharma.com/.

Making Sense of Today’s US Markets with Richard Carleton & Jason Paltrowitz | AFTER MARKET SPECIAL

Curious about what’s happening in the US stock market? We invited two market experts to discuss the recent rally in the US on our AFTER MARKET programs and compiled both interviews for your listening pleasure.

Firstly, JB & Bear are joined by their third ever guest on AFTER MARKET – Richard Carleton, CEO of the CSE – Canadian Securities Exchange. In this “After Hours” segment we tap the expert to better understand the recent stock market rally in the face of the global pandemic.

Here’s a highlight of everything discussed on this podcast:

0:35 – Introducing Richard Carleton, CEO of the Canadian Securities Exchange
2:35 – Understanding performance attribution within indices
5:00 – What happens to the stock market when things go back to “normal”?
7:05 – Investing FOMO and behavioural economics
11:20 – Why it’s hard to beat ETF and Mutual Fund returns (but the lizard brain doesn’t care)
13:55 – Money is effectively “free” – how does this impact the equity markets? (Warning: inflation alert!)

Following Richard’s interview, JB & Bear are joined by their fourth guest on AFTER MARKET – Jason Paltrowitz, EVP of  @OTC Markets Group In this “After Hours” segment we tap the expert to better understand how the US markets and economy are proving their resiliency in historically difficult conditions.

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

Draganfly: This drone pioneer aims to become the world’s go-to provider for “unique” data

While it was only in the past several years that drones gained broad recognition as valuable commercial tools, these amazing machines have actually been at work improving our lives for decades. Draganfly (CSE:DFLY) has been serving companies and governments looking for high-quality drones and related services for over 22 years, selling to markets as large and important as public safety, agriculture and industrial inspection.

That list is just a start says Draganfly Chief Executive Officer Cameron Chell. Public Entrepreneur caught up with Chell recently to discuss Draganfly’s development to date and where the company is heading in the medium and long terms. According to Chell, the sky’s the limit when it comes to the value Draganfly can bring to society – and Draganfly shareholders – given time. And that includes playing a role in helping the world manage the ongoing COVID-19 crisis.

Drones have been available for commercial applications for a generation, but interest and real-world use have really gained momentum in the past few years. Why?

I think what’s driving the momentum is the actual practical use of drones. It’s sensor functionality, battery life, cost and actual regulation and awareness of drones, and people getting more comfortable with the functions they create. Basically, I think it’s the convergence of all the technologies coming together, and certainly the COVID-19 pandemic has highlighted the fact that this is a tool that can be used in a contactless way, as a resource multiplier, or to carry out functions that humans don’t necessarily have to do now and risk close contact.

There are many competitors in the industry. How does Draganfly’s experience over more than two decades give you an edge?

We are the oldest commercial manufacturer of drones in the world. The first drone ever credited with saving a human life sits in the Smithsonian today, and it was a Draganfly drone fitted with a thermal camera. What separates us is our technology and our software.

You mentioned COVID-19. Draganfly recently initiated “pandemic drone” test flights. Tell us more.

On the pandemic side, the software we use can do two things: it can measure social distancing and mask-wearing, so it can measure how well people are carrying out what officials are putting in place. And the second thing it can do is measure vital signs.

The real advantage of our technology is that we can, for the first time ever, really, start to provide real-time data on the effectiveness of things like mask-wearing and social distancing, and we can start to get real-time data on community health, as opposed to waiting to see how full hospitals become, or relying on models of where the pandemic might go.

In this case, we can have cameras measure social distancing and vital signs to determine infection rates within a crowd on the beach at a particular time of day, or what the infectious or respiratory potential is of a crowd in a football stadium. It doesn’t make a diagnosis, it doesn’t identify people, but it does come back and provide real-time data on where we think we’re at in terms of the infectious cycle at that moment. We provide both an aerial and fixed-base camera platform for different use cases.

What has been the response from local governments and others to the test flights?

From a technology standpoint and from a public official standpoint, the response has been overwhelmingly positive. They understand that this isn’t a scenario where people are being identified and profiled, but rather it’s providing real-time data. For the first time they may not only get a sense of potentially what the health consequences are to first responders or the public in general, but they can also start to monitor whether potential hotspots are emerging and whether policies are working to help start opening up economies again.

Who are some of the customers for Draganfly drones?

Draganfly has sold over 9,000 drones, primarily for public safety, but also to agriculture, construction and mining. It is all the industries you would expect, but our primary customers have been public safety, law enforcement and border patrol.

We’re seeing demand grow from that sector, but interestingly also for consumer safety and workplace safety. Imagine places such as theme parks, convention centres, factory floors or retail outlets, where you’ve got consumers coming in and management wants to ensure a couple of things. One is that their workforce is safe and not bringing in potentially infectious diseases, and then there is consumer safety and advocacy, where you might have a convention centre or a theme park that’s putting this type of system in place to benefit consumer confidence. An interesting concept that we see starting to develop is that the same way you and I get a weather report right now, we’re going to see the emergence of health reports.

Where do you see the drone industry in three to five years? And what does this mean for you as a company?

We are a North American manufacturer, so there’s lots of data security concern as it relates to foreign manufacturers. We really see ourselves growing in the domestic space or, quite frankly, amongst NATO or Five Eyes countries, to be able to provide drones and secure data delivery.

How do you make money in the drone business? Is it volume, or government and agency customers that generate recurring revenue, or the consumer market?

For sure, it isn’t from consumers. We think foreign manufacturers will continue to dominate that space.

For us, we will continue to do contract engineering for military applications. That’s just a staple of ours that provides a good base of income. Ultimately, our recurring income will be driven by data analytics and management. Today we build specific drones, devices, software and services for industry verticals in which we can provide hardware, software, services and data management that give our customers a competitive advantage in their industry.

We do sell drones to end users, and it is a growing market. However, we see demand being very strong in turnkey and subscription-based services. Companies aren’t necessarily looking for a drone and a pilot. There’s an element of that, but the bigger growth area is going to be more around turnkey service. I’m an insurance company and I want rooftop inspections for 5,000 homes a month, say, and I just want the data. And where Draganfly differentiates itself is that we’re really good at incorporating sensors and providing data you typically can’t get from other drone providers.

You are also helping to find landmines. Tell us more about this work.

This is a great example of a large untapped market that requires specialized equipment and software, not to mention data analytics and management. We’re working with a partner called Windfall Geotek, which has a ton of experience in this space, but they need a specialized drone with specialized sensors in order to provide their AI with the data that is beyond just magnometer data. We expect to roll that out in force over the next eight months.

What’s really exciting about this is not just being able to uncover mines without having people and dogs at risk, but also the amount of data that we collect – the patterns of mines, the number of mines missed in the past, the areas and the regions. Building a database of this type of stuff really helps the AI to be able to uncover more mines.

Your acquisition of Dronelogics Systems earlier this year marked a big change. What does this deal mean for Draganfly?

Dronelogics is a 10-year-old company with a fantastic reputation and incredible management. They do great integration work with multiple drone systems.

We intend to make more acquisitions, and the two principals at Dronelogics are key for us to build on top of our acquisitions and do proper integration. The other advantage of the acquisition is that they sell a lot of other manufacturers’ products, but as we get moved into that mix, we become vertically integrated a bit whereby they can provide either Draganfly products and/or our contract engineering services.

You’ve built up a strong team. Tell us about the group.

Andy Card is former White House Chief of Staff under George W. Bush. He was also Secretary of Transportation. His endorsement of our company is important. He only sits on two boards: us and BNSF, which is the massive railroad system. To have his ear, his insight and global perspective has been fantastic. He works with us on public relations, but also in terms of being able to provide business development insight into both the government and industrial worlds.

We’ve also got John Mitnick. He’s the former General Counsel of Raytheon and former General Counsel of Homeland Security. John’s role is insight and advisory, but also penetrating us into the government’s position of not moving forward with foreign drones and looking to North American manufacturers.

Julie Myers is on our advisory board. She’s former Assistant Secretary of Homeland Security. We also have Dr. Jack Chow, who was the first Assistant Director-General of the WHO on HIV/AIDS, Tuberculosis and Malaria, who is a big drone advocate and has been for 10 years.

Is there any other core message the market needs to know about Draganfly?

Draganfly is a data company that makes drones, devices and software, and provides services to create and provide better data. The strategic differentiator for Draganfly is that we provide data to our customers that basically nobody else can. An example would be the landmine data, or health measurement data. You might think of us today as a drone manufacturer, but three years from now, or five years from now, I believe Draganfly will be a prominent business brand you will associate with data analytics and management. That’s where you go to get your data, or that’s where industry goes to get its data. Data is valuable, but unique data is priceless, and the name of the game for Draganfly is to create unique data.

This story was featured in the Public Entrepreneur magazine.

Learn more about Draganfly
at https://draganfly.com/.

Michael Frank on the Race to Fight Infectious Diseases | #HashtagFinance

CSE’s Barrington Miller chats with Michael Frank, CEO of Revive Therapeutics Ltd. (CSE:RVV) about his company’s ambitions to enter Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.

With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury
from organ transplantation.

Related links
https://revivethera.com/
https://thecse.com/en/listings/life-sciences/revive-therapeutics-ltd

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS